This review forms part of a series of annual updates that summarize the evidence base for atopic eczema (AE). It provides a summary of key findings from 12 systematic reviews (SRs) that were published or indexed during 2014, and focuses on the treatment and prevention of AE. For an update of SRs on the epidemiology, mechanisms of disease and methodological issues, see Part 1 of this update. Although phototherapy and various systemic medications (including ciclosporin, azathioprine and methotrexate) are commonly used to treat AE, many of these have not been robustly assessed in head-to-head randomized controlled trials. Educational interventions may improve AE severity and quality of life for children and their families. Intake of probiotics prenatally and postnatally may help prevent AE, but there is little evidence to suggest a role in the treatment of AE. Although no benefit was found for allergen avoidance in preventing AE, the use of immunotherapy to treat AE-associated aeroallergen sensitivity requires further evaluation. There is insufficient evidence for Vitamin D supplementation for the treatment of AE This overview of reviews provides a succinct guide for clinicians and patients wishing to remain up to date with the most recent evidence for the treatment and prevention of AE.
Background
Atopic eczema (AE) is a common inflammatory skin disease. The aim of this evidence update is to highlight the clinical and research implications from recent systematic reviews (SRs) published or indexed during 2014. This update summarizes the findings of AE SRs on treatment and prevention. For an update of SRs on the epidemiology, mechanisms of disease and methodological issues, see Part 1 of this update. Similar evidence updates on AE have been published previously, along with the details of the search methods used. 1 
Treatment of atopic eczema Systemic treatments
Systemic treatments for AE were reviewed by Roekevisch et al. 2 The review assessed 34 randomized controlled trials (RCTs), the majority of which were placebo-controlled and included adult participants. The quality of included trials was assessed.
The authors recommended short-term use of ciclosporin as a first-line treatment for AE, based on reasonable evidence of efficacy in improving clinical signs of AE derived from 14 RCTs. These 14 studies comprised 5 placebo-controlled studies, 6 comparisons of active interventions and 3 dose/formulation studies, the majority of which involved adult participants. Weaker evidence supported second-line treatment recommendation for azathioprine, with interferon-c as a possible third-line option for severe AE. Methotrexate and mycophenolate were recommended for maintenance treatment. Pimecrolimus was included as a possible short-term option for moderate to severe AE.
There was either limited or inconsistent evidence for the use of montelukast, intravenous immunoglobulin or systemic glucocorticoids. Large head-to-head RCTs evaluating long-term treatment options are warranted, particularly for children.
Phototherapy
Garritesen et al.
3 assessed the evidence supporting phototherapy for AE (19 RCTs with 905 participants). Meta-analysis was not possible because of significant heterogeneity. Phototherapy generally improved clinical AE scores, although the quality of the included RCTs was limited. The best quality evidence was for ultraviolet (UV)A1 and narrowband UVB.
Dietary interventions
Probiotics. One meta-analysis 4 evaluated the evidence for probiotics in treating AE, assessing 25 trials with 1599 participants. The authors conducted meta-analyses on different populations, but these results are difficult to interpret because of the significant heterogeneity of the included studies, and the strong possibility of publication bias. Previous SRs of probiotics for the treatment of AE have consistently concluded a lack of treatment effect in children. 5, 6 Vitamin D supplementation. One review 7 included four small trials (three RCTs, one nonrandomized trial) evaluating different regimens of vitamin D supplementation. Meta-analysis was not possible. There is currently insufficient evidence to support Vitamin D supplementation in the treatment of AE.
Psychological and educational interventions. A Cochrane review 8 evaluated psychological and educational interventions. Nine RCTs investigated educational interventions (2004 children/adolescents with AE and their caregivers). Meta-analysis was not possible. The authors concluded that there is some evidence of benefit on AE severity and quality of life for both children and their families from educational interventions used alongside standard care. The evidence is less clear for psychological interventions as only 1 trial with 44 participants was included.
Sublingual immunotherapy
Sublingual immunotherapy (SLIT) has been proposed as a treatment for patients with AE who also have aeroallergen sensitivity. One review 9 included four studies investigating SLIT for house dust mite (two RCTs, one partly randomized study, 1 noncontrolled, nonrandomized study) and one cohort study investigating a combination of inhalant allergens (344 adults and children). The authors concluded that there was weak evidence in favour of SLIT, but there were significant methodological limitations of both the review and the included studies. SLIT is not currently available on the National Health Service, and is unlikely to become so without stronger evidence of benefit.
Alpine climate treatment
Fieten et al. 10 analysed 15 observational studies of highly variable size and treatment duration. There were very significant methodological limitations, and most were performed by investigators assessing the effectiveness of their own therapy. The review concluded that alpine climate therapy reduces AE severity and the need for topical corticosteroid treatment, but the poor quality of evidence and impractical nature of the intervention make it an unpromising intervention for most patients.
Topical sodium cromoglicate cutaneous emulsion
A review by Stephens et al.
11 compared sodium cromoglicate, a synthetic anti-inflammatory drug, with vehicle for the treatment of children with AE. Both authors act as consultants for the manufacturers of this formulation. Of the 3 RCTs, which assessed 490 participants, only 1 has been published to date. Metaanalysis indicated a small benefit from sodium cromoglicate compared with vehicle (mean difference in SCORing Atopic Dermatitis (SCORAD) of À2.52 (95% CI À5.36 to À0.29), but the clinical relevance of this finding is unclear. Sodium cromoglicate is not widely available as a skin preparation.
Prevention of atopic eczema Allergen avoidance
One review assessed a range of allergen avoidance strategies and concluded that these did not significantly reduce the incidence of AE. 12 The type and ª 2016 British Association of Dermatologists duration of the intervention and follow-up varied considerably, making it difficult to compare these trials in a meta-analysis. It is currently impossible to draw conclusions about the role for allergen avoidance in preventing AE.
Probiotics
Two SRs were published investigating the role of probiotics in the primary prevention of AE. One review evaluated AE occurrence in infants who received probiotics either prenatally and/or postnatally, 13 analysing trials, of which 13 involved 'high allergic risk' participants and 3 'general' populations, with a total of 3495 participants. The authors concluded that probiotics help prevent AE (OR = 0.64, 95% CI 0.56-0.74, P < 0.001) when administered during the final weeks of pregnancy and the first 3 months of life. However, there was no quality assessment of the included trials and there was significant heterogeneity of studies within the meta-analysis.
The second meta-analysis 14 found that use of probiotic supplements beginning in gestation through the first 6 months of life reduced the incidence of AE, quoting a mean reduction rate of 26% (range 13-33%). Again, significant heterogeneity existed between the included RCTs, and specific details on probiotic regimens were not included. While the use of probiotics prenatally and continued postnatally may reduce AE incidence, there is as yet no consistent evidence for a specific bacterial strain or regimen that can be recommended.
Maternal diet
The role of maternal diet during pregnancy and lactation in the development of AE in babies is unclear. Netting et al. 15 reviewed the evidence from 26 trials, comprising 5 RCTs, 2 nonrandomized comparative studies, 16 prospective cohort studies, and 3 interventional studies.
There was considerable variation in the types of dietary manipulation employed. Most studies excluded eggs and dairy, but others excluded fish, meat, fermented foods, soya and/or peanuts. The trials varied in the timing of the dietary manipulation, with some involving restrictions throughout pregnancy and others in late pregnancy and/or lactation.
No firm conclusions can be drawn regarding the role of maternal diet in preventing AE.
Conclusion
The significant variation in trial design, methodology and choice of outcome measures for AE trials makes it difficult to draw conclusions about whether or not interventions confer benefit to patients. In this review, not all SRs evaluated the quality of included evidence, and some combined data that were not equivalent. It is therefore imperative that efforts are made to improve trial quality, and that SRs use sound methodology in order to prevent misleading results.
We strongly recommend that trials and SRs are preregistered 16, 17 and are reported using appropriate guidelines (CONSORT 18 and PRISMA 19 ). The Global Resource for Eczema Trials (GREAT) database 20 is a useful resource for identifying further SRs and RCTs for AE treatment, and is freely available.
Learning points
• Although ciclosporin, azathioprine and methotrexate are commonly used to treat AE, evidence supporting their relative efficacy is limited.
• There is some evidence to support educational interventions, phototherapy and topical sodium cromoglicate cutaneous emulsion for AE treatment.
• There is insufficient evidence to support use of vitamin D supplements, alpine climate treatment or probiotics for the treatment of AE.
• Sublingual immunotherapy for patients with AE and aeroallergen sensitivity may be beneficial, but requires further evaluation and is not commonly available.
• The use of probiotics prenatally and continued postnatally may help prevent AE • There is currently no evidence for the role of allergen avoidance in the prevention of AE, but this may be due in part to the combination of multiple allergen avoidance strategies and highly variable study designs.
CPD questions Learning objective
To demonstrate knowledge of the findings of recent systematic reviews on atopic eczema.
Question 1
Which of the following statements regarding the use of probiotics in atopic eczema (AE) is true? (a) There is evidence that prenatal administration of probiotics reduces the development of AE in infants. (b) There is evidence that administration of probiotics prenatally and continued postnatally reduces the development of AE in infants. (c) It is possible to recommend specific probiotic regimens to prevent AE. (d) Randomized controlled trials (RCTs) investigating the use of probiotics in AE can be compared easily using meta-analyses. (e) There is consistent evidence indicating a role for probiotics in the treatment of established AE.
Question 2
For which of the following treatments for atopic eczema (AE) has robust evidence of effectiveness been found?
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